Treatment of dementia and cognitive impairment: What can we learn from the Cochrane Library

Journal of the Neurological Sciences

Volumn 283, Issue 1-2, 2009, Pages 207-210

  Bereczki, Dániel ^a   Szatmári, Szabolcs ^b  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Cochrane; Dementia; Evidence based medicine; Systematic review; Treatment

Indexed keywords

CYCLOSERINE; DONEPEZIL; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; COCHRANE LIBRARY; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; MEDLINE; MULTIINFARCT DEMENTIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

COGNITION DISORDERS; DATABASES AS TOPIC; DEMENTIA; HUMANS; INTERNET; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 67650106100     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.02.351     Document Type: Article

References (27)

1. World Health Organization. International Classification of Diseases - ICD-10, Version 2007. URL: http://www.who.int/classifications/apps/icd/icd10online. Accessed: January 2, 2008.
2. Launer L.J., Andersen K., Dewey M.E., Letenneur L., Ott A., Amaducci L.A., et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 52 (1999) 78-84
3. Kalache A., and Keller I. The greying world: a challenge for the twenty-first century. Sci Prog 83 Pt 1 (2000) 33-54
4. United States National Library of Medicine. PubMed. URL: http://www.ncbi.nlm.nih.gov/sites/entrez/. Accessed: January 2, 2008.
5. Baskys A., and Hou A.C. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging 2 (2007) 327-335
6. Omerovic M., Hampel H., Teipel S.J., and Buerger K. Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas. World J Biol Psychiatry 9 (2008) 69-75
7. Sink K.M., Holden K.F., and Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293 (2005) 596-608
8. Waldemar G., Dubois B., Emre M., Georges J., McKeith I.G., Rossor M., et al., EFNS. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14 (2007) e1-e26
9. Szatmári S., and Whitehouse P.J. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev 1 (2003) 10.1002/14651858.CD003119 Art. No.: CD003119
10. Szatmári S, Bereczki D. Procaine treatments for cognition and dementia. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD005993, doi:10.1002/14651858.CD005993.pub2.
11. Yan H., Li L., and Tang X.C. Treating senile dementia with traditional Chinese medicine. Clin Interv Aging 2 (2007) 201-208
12. Huang Y., Lai X.S., and Tang A.W. Comparative study of the specificities of needling acupoints DU20, DU26 and HT7 in intervening vascular dementia in different areas in the brain on the basis of scale assessment and cerebral functional imaging. Chin J Integr Med 13 (2007) 103-108
13. Purandare N., Swarbrick C., Fischer A., and Burns A. Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England. Int J Geriatr Psychiatry 21 (2006) 961-964
14. Ramassamy C., Longpré F., and Christen Y. Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?. Curr Alzheimer Res 4 (2007) 253-262
15. Dos Santos-Neto L.L., de Vilhena Toledo M.A., Medeiros-Souza P., and de Souza G.A. The use of herbal medicine in Alzheimer's disease-a systematic review. Evid. Based Complement. Altern. Med. 3 (2006) 441-445
16. Kennedy D.O., and Scholey A.B. The psychopharmacology of European herbs with cognition-enhancing properties. Curr Pharm Des 12 (2006) 4613-4623
17. Cochrane A.L. 1931-1971: a critical review, with particular reference to the medical profession. Medicines for the year 2000 (1979), Office of Health Economics, London 1-11
18. The Cochrane Library, Issue 3 (2008), Wiley, Chichester
19. McShane R., and Collins H. Cochrane Dementia and Cognitive Improvement Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) (2008) Issue 2. Art. No.: DEMENTIA
20. In: Higgins J.P.T., and Green S. (Eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration (2008). http://www.cochrane-handbook.org Available from www.cochrane-handbook.org
21. Malouf R., and Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 1 (2004) 10.1002/14651858.CD004395.pub2 Art. No.: CD004395
22. Craig D., and Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2 (2004) 10.1002/14651858.CD004744.pub2 Art. No.: CD004744
23. McShane R., Areosa Sasstre A., and Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2 (2006) 10.1002/14651858.CD003154.pub5 Art. No.: CD003154
24. Tabet N., and Feldman H. Indomethacin for Alzheimer's disease. Cochrane Database Syst Rev 2 (2002) 10.1002/14651858.CD003673 Art. No.: CD003673
25. Jones R., Laake K., and Oeksengaard A.R. D-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev 2 (2002) 10.1002/14651858.CD003153 Art. No.: CD003153
26. Scott H.D., and Laake K. Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev 3 (2001) 10.1002/14651858.CD003160 Art. No.: CD003160
27. Birks J., and Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2 (2007) 10.1002/14651858.CD003120.pub2 Art. No.: CD003120